Tag: Somatrem

Somatrem, one of the first recombinant human growth hormone therapies, was discontinued in 2004 after the development of a bioequivalent version with fewer potential side effects. As with all medications, the original Protropin formulation of somatrem carried a range of potential adverse reactions, from mild injection-site irritation to more serious metabolic and neurological issues.

While many search for 'what is the use of somatrem tablet?', it is a common misconception, as somatrem was never manufactured in a tablet form. Instead, this recombinant human growth hormone (hGH) was developed for administration via injection and has since been largely replaced by the structurally identical somatropin.

In 1985, the first commercially available recombinant human growth hormone was introduced by Genentech under the brand name Protropin. This medication, known generically as somatrem, was a synthetic version of human growth hormone designed to address growth failure in both children and adults. The answer to "what does somatrem do?" lies in its role as a precursor to modern growth hormone therapy.